ledisa glp-1 patch Patches GLP-1 patches are changing the
Description
Novo Nordisk (the maker
GLP-1RA use lowered cardiovascular, kidney, and mortality risks in patients with lupus and diabetes
The GLP-1 Receptor Agonist market size reached USD 15.25 Billion in 2024 and is expected to register a revenue CAGR of 21.7%
This temporary allowance enabled pharmacies to meet surging demand, particularly among patients seeking anti-obesity medications who now represent approximately 83% of the compounded GLP-1 market
These are not FDA approved medications
Note: Trulicity is administered once a week, on the same day each week
